News | May 13, 2026
Mankind’s Rajeev Juneja contributes Rs. 9.17 crore to National Defence Fund
This marks the second consecutive year that Juneja has made a personal contribution towards supporting the armed forces
This marks the second consecutive year that Juneja has made a personal contribution towards supporting the armed forces
Pan-India multidisciplinary program aims to improve coordinated care for patients with chronic kidney disease and heart failure
The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio
The move targets long-standing bottlenecks in MSC science, including cell-to-cell variability, immunocompatibility concerns, and inefficient manufacturing workflows
NEJM study shows strong protection across strains
The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
The agreement targets a long-standing technical hurdle in the field: maintaining chemical purity as RNA constructs extend beyond 100 nucleotides
Successful inspection outcome strengthens company’s regulatory compliance and manufacturing standards in China
With 267 million tobacco users, improving access to evidence-based cessation tools is seen as critical
Subscribe To Our Newsletter & Stay Updated
